Geoffrey Alan Watson

Author

Also Known As

G A Watson, G Watson, G. A. Watson, G. Watson, G.A. Watson, Ga Watson, Geoffrey A. Watson, Geoffrey Alan Watson, Geoffrey Watson

Publications

314

Citations

H-Index

Concepts

All Affiliations

Princess Margaret Cancer Centre Tel Aviv Sourasky Medical Center Tel Aviv University University of Toronto National Institutes of Health

About

Geoffrey Alan Watson is an author at Princess Margaret Cancer Centre specializing in oncology, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	49
2	Pharmacology	2	2	49
3	Immunology	1	1	13
4	Obstetrics	1	1	36
5	Autoimmunity	1	1	13

Geoffrey Alan Watson

Publications

120

Citations

H-Index

Page 1

	Year	Citations
Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer Geoffrey Alan Watson, Oana Deac, Razia Aslam, Clinical Breast Cancer Breast OncologyOncologyReal-world ExperienceMedicineCancer Management	2018	36
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab Geoffrey Alan Watson, Enrique Sanz‐García, Wenjiang Zhang, Journal for ImmunoTherapy of Cancer	2022	23
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events Helena J. Janse van Rensburg, Zhihui Liu, Geoffrey Alan Watson, British Journal of Cancer	2023	15
Toxicities in immunotherapy: Can they predict response? Lisa Prior, Emily Harrold, Connor O’Leary, Journal of Clinical Oncology ImmunotoxicologyImmunologyImmunoeditingImmunotherapeuticsImmune System	2016	13
Progressive multifocal leukoencephalopathy secondary to rituximab-induced immunosuppression and the presence of John Cunningham virus: a case report and literature review Deirdre Kelly, Bernadette Monaghan, Eileen M. McMahon, Radiology Case Reports	2016	12
Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE Geoffrey Alan Watson, Zachary Veitch, Daniel Shepshelovich, British Journal of Cancer	2022	11
Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223 Esmail Mutahar Al-Ezzi, Husam Alqaisi, Marco Iafolla, Cancer Medicine	2021	10

Page 1